Dendreon Corporation (NASDAQ: DNDN)- Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients. The Company’s product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. Its advanced product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy that has completed three Phase III trials for the treatment of metastatic, castrate-resistant, (also known as androgen-independent or hormone-refractory) prostate cancer.
CEOWORLD Top 5 Analyst Calls of the Week- DNDN, INSP, MCP, SIRI, VICL
Latest posts by Megan Batchelor
- What Successful E –Commerce Markets are doing to Stay Relevant - 01/16/2018
- Top Non-U.S. Business Schools For Executive MBA In 2018 - 01/12/2018
- 3 Tips for Handling a Customer Service Position - 01/06/2018